I am still in, but the fact of the matter is baricitinib is already approved and in use for RA and I suppose they have lots available.

I suppose if leronlimab had already been approved and in use and being manufactured and distributed, we would be at an advantage as well.

I don' think this shuts us out, but it is definitely a challenge to us and other therapeutic hopefuls.

I think the people talking sh*t about Nader and blaming shorts or longs are totally missing the conversation that is happening from Trump, from Fauci etc.

This is the real world and in any industry, a big company is going to have advantages over a little start-up. I am not being a naysayer, I think our trial results will be better than their trial results. But they also had a bigger trial.